A study showing that therapeutic strategies combining cetuximab, IL-2, and IL-15 could activate phenotypic and dysfunctional blood NK cells and improve cytotoxicity in CRC patients provided novel insights into CRC therapies based on ILs (110). Here, IL2 is linked to colorectal carcinoma.